Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ozurdex
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:formulation |
injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Triesence
|
| gptkbp:indication |
uveitis
macular edema vitreous hemorrhage |
| gptkbp:ingredients |
triamcinolone acetonide
|
| gptkbp:is_used_for |
treatment of eye conditions
|
| gptkbp:manager |
intravitreal injection
|
| gptkbp:manufacturer |
gptkb:Alcon_Laboratories
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:side_effect |
inflammation
eye pain increased intraocular pressure cataract formation |
| gptkbp:storage |
refrigerated
|